SSP Of Japan Now 93 Percent Owned By German Drug Maker
This article was originally published in PharmAsia News
Executive SummaryJapan's SSP has become at least 93 percent owned by German drug maker Boehringer Ingelheim, almost enough to make SSP part of a holding company of the investor. SSP is Japan's third-largest producer of over-the-counter drugs, specializing in those considered easy to take. Boehringer Ingelheim expects to increase its stake in SSP to nearly 94 percent, at which point the German firm would take SSP off the stock market. (Click here for more - a subscription may be required
You may also be interested in...
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.